Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...
Oncologic equivalence of brand-name vs generic imatinib in neoadjuvant KIT exon 11 GIST: A real-world international cohort study. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I.
People who have received a cancer diagnosis are living longer than ever, according to a new report from the American Cancer Society (ACS). Decades of cancer research have led to more effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results